Simulations Plus Releases GastroPlus Version 8.6
Interim release adds several user-requested functions
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has released version 8.6 of its industry gold-standard GastroPlus™ simulation software.
“The release of GastroPlus 8.6 adds several functions requested by a number of our users around the world, including”
Dr. Viera Lukacova, team leader for Simulation Technologies at Simulations Plus, said, “The release of GastroPlus 8.6 adds several functions requested by a number of our users around the world, including:
- Addition of population simulations in the drug-drug interaction (DDI) module
- Addition of minipig physiology – a preclinical species that is growing in popularity
- Integration with the latest version (7.1) of our ADMET Predictor™ property prediction software
- A number of minor bug fixes and user interface improvements”
Dr. Lukacova continued, “This release incorporates a number of important improvements to the drug-drug interaction module and now makes it possible for scientists to see the expected distribution of drug-drug interaction effects across selected populations of adults and children. A number of bug fixes and modifications were implemented to accommodate more advanced simulations and to prevent certain types of inappropriate inputs that might have been entered by less-experienced users.”
Mr. John DiBella, vice president for marketing and sales for Simulations Plus, added, “This interim release of GastroPlus addresses a number of requested features that we wanted to deploy to our users as soon as possible rather than waiting for the next major release. Following our recently announced acquisition of Cognigen, this release also helps us realize one of our stated goals of expanding the use of our technology into clinical pharmacology groups, which we feel is a significant growth area for the company. GastroPlus continues to enjoy its industry-leading reputation for predictive accuracy. This release demonstrates our commitment to maximizing the productivity of our users at the earliest possible date.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Our recently announced acquisition of Cognigen, Inc. of Buffalo, NY, expected to close on September 2, will add top-quality clinical trial data analysis to our offerings, and will more than double our staff from 30 to 65, add nearly 50% to revenues, and add to earnings in the coming fiscal year that begins September 1. We also provide a productivity tool called Abbreviate! for PCs. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, continued success with testing our new molecules for activity against the malaria parasite and for other properties necessary for molecules to become drugs, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.